Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual five‑grass pollen tablet immunotherapy for grass pollen allergic rhinoconjunctivitis
2004-001910-15Phase 2Completed
- Sponsor
- Stallergenes Greer
- Start
- Oct 2004
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Oralair in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Stallergenes Greer. Primary endpoint: Rhinoconjunctivitis Total Symptom Score. Started Oct 2004; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2004-001910-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001910-15.